GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (NAS:SLS) » Definitions » Cyclically Adjusted PS Ratio

SELLAS Life Sciences Group (SELLAS Life Sciences Group) Cyclically Adjusted PS Ratio : (As of May. 15, 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


SELLAS Life Sciences Group Cyclically Adjusted PS Ratio Historical Data

The historical data trend for SELLAS Life Sciences Group's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Cyclically Adjusted PS Ratio Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 - - -

SELLAS Life Sciences Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SELLAS Life Sciences Group's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, SELLAS Life Sciences Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Cyclically Adjusted PS Ratio falls into.



SELLAS Life Sciences Group Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

SELLAS Life Sciences Group's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, SELLAS Life Sciences Group's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/129.4194*129.4194
=0.000

Current CPI (Dec. 2023) = 129.4194.

SELLAS Life Sciences Group Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 543.250 99.695 705.225
201406 582.750 100.560 749.995
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.000 108.420 0.000
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.183 109.897 0.216
202103 0.383 111.754 0.444
202106 0.124 114.631 0.140
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.063 121.301 0.067
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SELLAS Life Sciences Group  (NAS:SLS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


SELLAS Life Sciences Group Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group (SELLAS Life Sciences Group) Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Executives
Angelos M. Stergiou director, officer: President and CEO C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583
Barbara A Wood officer: EVP, Gen. Counsel, Corp. Sec. 58 S SERVICE RD, MELVILLE NY 11747
John Thomas Burns officer: VP, Finance & Corp Controller 16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Robert Francomano officer: Chief Commercial Officer C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022
Nicholas J. Sarlis officer: Chief Medical Officer and SVP C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583
Stephen F Ghiglieri director C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David A Scheinberg director 325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
John Varian director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund` 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Equilibria Capital Management Ltd 10 percent owner O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08

SELLAS Life Sciences Group (SELLAS Life Sciences Group) Headlines

From GuruFocus